Understanding the treatment effect modification of mono- or combination PD-1/PD-L1 inhibitor therapies on survival outcomes in patients with metastatic renal cell carcinoma: What does the literature say?

Neha Sati,Devon J Boyne,D.R. Brenner,P. Arora

Understanding the treatment effect modification of mono- or combination PD-1/PD-L1 inhibitor therapies on survival outcomes in patients with metastatic renal cell carcinoma: What does the literature say?

2020

Neha Sati
Devon J Boyne
D.R. Brenner
P. Arora

e17097Background: PD-1/PD-L1 inhibitors are immune checkpoint inhibitors widely used in the treatment of metastatic renal cell carcinoma (mRCC) and other cancers. There is a lack of understanding r...

Keywords:

Oncology
Renal cell carcinoma
in patient
treatment effect
PD-L1 inhibitor
Internal medicine
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations